

Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer

Hyeon Woo Kim, Jae Eun Park, Minjae Baek, Heejoo Kim, Hwee Won Ji, Sung Hwan Yun, Dawoon Jeong, Juyeon Ham, Sungbin Park, Xinpei Lu, Han-Sung Kang, and Sun Jung Kim

Supporting Information

Table S1. Primer sequences used for qRT-PCR and MSP employed in this study

Gene	Forward primer (5'→3')	Reverse primer (5'→3')	Supplier
qRT-PCR			
<i>GAPDH</i>	ACATCGCTCAGACACCATG	TGTAGTTGAGGTCAATGAAGGG	IDT
<i>MMP1</i>	GACAGATTCTACATGCGCAC	CCCTTTGAAAAACCGGACTTC	Bioneer
MSP			
<i>MMP1 M</i>	ATTTTAAATAAGATGTGTGCG	AACCATCAAAACCAATCTTTT	Bioneer
<i>MMP1 U</i>	ATTTTAAATAAGATGTGTGTG	AACCATCAAAACCAATCTTTT	

Figure S1. Uncropped Western blots. The boxed areas in the images are shown in the main text.

Fig. 1D




Figure S2. Induction of downregulation of MMP1 in the MCF-7 and MCF-7/tamR cells. Stable MMP1 knockdown cells [MCF-7/tamR/shMMP1 (A) and MCF-7/shMMP1 (B)] were developed using two shRNAs that target different MMP1 sites (#1 and #2). Expression of MMP1 was then evaluated by qRT-PCR. shNC; control shRNA. All results are reported as the means \pm SE of three independent experiments. * $P < 0.01$

